Search
for
Sort by
Research 331–360 of 334
- Androgenetic Alopecia: A Chronic or Pubertal Onset Disease Retarded by Blood Donation
- Therapeutic-effects-of-growth-factor-cocktail-including-fibroblast-growth-factor-9-in-patients-with-androgenetic-alopecia-a-split-study
- Evaluation of the efficacy and safety of topical and oral treatments on hormonal and androgenetic alopecia
- Minoxidil to Treat Androgenetic Alopecia in Men and Women: What is It & How does It Work?
- Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation
- Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?
- <i>Zizyphus jujuba</i>protects against ibuprofen-induced nephrotoxicity in rats
- Characterization of minoxidil/hydroxypropyl-β-cyclodextrin inclusion complex in aqueous alginate gel useful for alopecia management: Efficacy evaluation in male rat
- Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery
- Colchicine in Managing Skin Conditions: A Systematic Review
- Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia
- PROSPECT OF UTILIZING EXPIRED HOMOLOGOUS PLATELET CONCENTRATES AS AN ALTERNATIVE SOURCE OF GROWTH FACTORS AND CYTOKINES IN CLINICAL SETUP FOR BETTER WOUND CARE AND HEALING
- A randomized, double-blind controlled clinical study to evaluate the efficacy and safety of minoxidil topical 2% nanosuspension with aqueous base in the treatment of androgenetic alopecia areata
- Protective role of Nigella sativa in chemotherapy-induced alopecia
- Combination of herbal extracts and platelet-rich plasma induced dermal papilla cell proliferation: involvement of ERK and Akt pathways
- BCG'osis
- Pre-clinical non-viral vectors exploited for<i>in vivo</i>CRISPR/Cas9 gene editing: an overview
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
- A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Worldwide Clinical and Real-World Exposure to Baricitinib
- Androgenetic Alopecia: Therapy Update
- The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
- The diagnosis and treatment of iron deficiency and its potential relationship to hair loss
- Alopecia areata: An update
- TOXIC EPIDERMAL NECROLYSIS